Psychotropic Drug-Induced Weight Gain Alleviated with Orlistat: A Case Series

Weight gain is a common side effect associated with antidepressant, anxiolytic, and antipsychotic drug use. Obesity is a risk factor for several other disorders, including hypertension, diabetes, and coronary artery disease. To date, there have been few safe, well-tolerated, and effective pharmacological agents available to alleviate weight gain in general, and virtually no studies specific to psychiatric drug-induced weight gain. This case series looks at the use of orlistat, a reversible inhibitor of lipases approved by the US Food and Drug Administration for obesity management, naturalistically in 13 patients with weight gain secondary to psychotropic drug use. The results showed that orlistat, administered in 3 daily doses with meals, was safe, well-tolerated, and effective, resulting in an average weight loss of 35% during an acute treatment period of about 3 months.

Authors

Institutions

Publication Details

Journal
Psychopharmacology Bulletin
Published
2025-08-12
DOI
https://doi.org/10.64719/pb.4191
Citations
41
Primary Topic
Pharmacology and Obesity Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Psychotropic Drug-Induced Weight Gain Alleviated with Orlistat: A Case Series

Thomas L. Schwartz, Maurizio Fava, and Mark Beale
41 citations
Psychopharmacology Bulletin
Pharmacology and Obesity Treatment
article

Psychotropic Drug-Induced Weight Gain Alleviated with Orlistat: A Case Series

Thomas L. Schwartz, Maurizio Fava, and Mark Beale
article en
41 citations

Abstract

Weight gain is a common side effect associated with antidepressant, anxiolytic, and antipsychotic drug use. Obesity is a risk factor for several other disorders, including hypertension, diabetes, and coronary artery disease. To date, there have been few safe, well-tolerated, and effective pharmacological agents available to alleviate weight gain in general, and virtually no studies specific to psychiatric drug-induced weight gain. This case series looks at the use of orlistat, a reversible inhibitor of lipases approved by the US Food and Drug Administration for obesity management, naturalistically in 13 patients with weight gain secondary to psychotropic drug use. The results showed that orlistat, administered in 3 daily doses with meals, was safe, well-tolerated, and effective, resulting in an average weight loss of 35% during an acute treatment period of about 3 months.

Psychopharmacology BulletinVol. 37(1)
SUNY Upstate Medical University (US)
Good health and well-being
Pharmacology and Obesity Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Psychotropic Drug-Induced Weight Gain Alleviated with Orlistat: A Case Series — Thomas L. Schwartz, Maurizio Fava, et al. · Psychopharmacology Bulletin (2025) | TGRS Research Map | TGRS